Biogen’s biosimilar Tofidence approved by FDA
Betsy Goodfellow | October 2, 2023 | News story | Medical Communications | Actemra, Biogen, FDA, Musculo-skeletal disorder, Tofidence
Biogen has announced that the US Food and Drug Administration (FDA) has approved Tofidence (tocilizumab-bavi) as an intravenous formulation, a biosimilar monoclonal antibody referencing Actemra.
The drug is approved for the treatment of moderately to severely active rheumatoid arthritis, polyarticular juvenile idopahic arthritis, and systemic juvenile idiopathic arthritis. Tofidence is the first biosimilar of this drug to be approved in the US.
The FDA’s approval of the drug followed comprehensive analytical, non-clinical and clinical data submitted to the FDA in September 2022. Also, a randomised, double-blind, single-dose, three-arm, parallel phase 1 study compared the pharmacokinetics, safety and tolerability of the drug with the US and EU reference tocilizumab in healthy volunteers. Then a randomised, double-blind, multi-dose, three-arm, parallel phase 3 study compared the drug with its reference to establish equivalent efficacy and comparable pharmacokinetic, safety and immunogenicity profiles in patients with rheumatoid arthritis inadequately controlled by methotrexate.
Ian Henshaw, global head of Biosimilars at Biogen, commented: “The approval of TOFIDENCE in the U.S. marks another positive step toward helping more people with chronic autoimmune conditions gain access to leading therapies. With the increasing numbers of approved biosimilars, we expect increased savings and sustainability for healthcare systems and an increase in physician choice and patient access to biologics.”
Betsy Goodfellow
Related Content
Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …
MedPharm announces US FDA inspection of North Carolina manufacturing facility
MedPharm has announced that the US Food and Drug Administration (FDA) has completed a successful …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
